NCT04086875 - A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer | Biotech Hunter

Enrollment

332

Participants

Timeline

Start Date

November 7, 2018

Primary Completion Date

September 24, 2024

Study Completion Date

September 24, 2024

Conditions

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Estrogen Receptor Positive TumorProgesterone Receptor Positive TumorPrognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8

Interventions

BEHAVIORAL

Focus Group

Participate in focus group

OTHER

Text Message

Receive text messages

OTHER

Best Practice

Receive usual care

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (7)

18901

Doylestown Hospital, Doylestown

19001

Jefferson Health - Abington, Abington

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

19114

Jefferson Health - Northeast (Aria Torresdale), Philadelphia

19148

Thomas Jefferson University - Methodist Hospital, Philadelphia

08080

Jefferson Health - South Jersey, Sewell

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Thomas Jefferson University

OTHER